|

Target trough IgG level 4-6 g/L Clinical Trials

1 actively recruiting trial

Also known as: Experimental

Pipeline

Phase 4: 1

Top Sponsors

  • CHU de Quebec-Universite Laval1

Indications

  • Relapsed Multiple Myeloma1
  • Multiple Myeloma, Refractory1
  • Cancer1

Other1 trial

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.